Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Rising awareness about hepatitis symptoms and growing need for early diagnosis through public education and increasing occurrence of hepatitis across the globe are fueling global market growth.
Zentalis Pharmaceuticals announced that Pfizer made a $25 million equity investment in the company.
Exogene nets $2 million to propel the development of its AI platform for T-cell receptor discovery and Healome spins out to deploy a ‘pro-healing’ platform with a focus on ocular surface diseases.
AviadoBio is celebrating orphan drug designations from both the U.S. FDA and the European Commission for AVB-101, a gene therapy intended to treat frontotemporal dementia (FTD).
BeiGene’s candidate drug tislelizumab for cancer succeeded in meeting the primary endpoint of overall survival in a global Phase III trial. Learn more about it here.
Weeks after Gilead Sciences raised concern over counterfeit HIV drugs, Johnson & Johnson has taken similar action against the distribution of counterfeit prescription drugs.
Microbiologics, Inc. the foremost provider of biomaterials and contract microbiology research services, is pleased to announce the acquisition of Cryologics
Cytovia Holdings, a biopharma company focused on natural killer (NK) cells, merged with special purpose acquisition company (SPAC) Isleworth Healthcare Acquisition Corp. to go public.
The U.S. Congress is calling for the coronavirus management plan to deliberate on the timeline for the approval and release of vaccines for children under 5 years old.
David Sabatini, who was ousted last year by the Whitehead Institute over allegations of sexual harassment, may have found a new home at the NYU Grossman School of Medicine.
New research suggests that treatment with anti-amyloid-beta protofibril antibody lecanemab is estimated to slow the rate of disease progression in patients with Alzheimer’s Disease.
GlaxoSmithKline exceeded expectations for its first-quarter sales and earnings forecasts. This was largely driven by its sales of Xevudy, an antibody treatment against COVID-19 it developed with Vir Biotechnology, and its Shingrix vaccine against shingles.